Coralyne chloride
(Synonyms: 氯化柯喃炔水合物) 目录号 : GC61965
Coralyne chloride 是一种具有强抗癌活性的原小檗碱化合物。Coralyne chloride 可以作为一种有效的拓扑异构酶 I (topoisomerase I) 毒性分子，诱导拓扑异构酶 I 介导 DNA 裂解。Coralyne chloride 可用于制备 Coralyne 衍生物，并可以用作 DNA 结合荧光探针制备。
Cas No.:38989-38-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Coralyne chloride is a protoberberine alkaloid with potent anti-cancer activities. Coralyne chloride acts as a potent topoisomerase I poison and induces Top I mediated DNA cleavage[2]. Coralyne chloride can be used for preparing coralyne derivatives as DNA binding fluorescent probes[3].
Coralyne (6.25-100 µM; 24-72 hours) has cytotoxicity effect on breast cancer cell lines. It against MCF-7, MDA-MB-231 and MCF-10A cells with IC50s of 76.4 uM, 76.4 uM, and 99 uM,respectively at 24 hours. And it against MCF-7, MDA-MB-231 and MCF-10A cells with IC50s of 21.9 uM, 19.1 uM, and 91 µM, respectively at 72 hours[1].Coralyne (25 µM; 48 hours) significantly downregulates cancer cell attachment of MCF-7 and MDA-MB-231 compared to the untreated controls. The percent of reduction in adhesion of MCF-7 is 55%, whereas 53% in reduction in the adhesion of MDA-MB-23 and 62% in reduction of MCF-10A,respectively[1].
References:
[1]. Seema Kumari, et al. Synergistic effects of coralyne and paclitaxel on cell migration and proliferation of breast cancer cells lines. Biomed Pharmacother. 2017 Jul;91:436-445.
[2]. D Makhey, et al. Coralyne and related compounds as mammalian topoisomerase I and topoisomerase II poisons. Bioorg Med Chem. 1996 Jun;4(6):781-91.
[3]. P M Pithan, et al. 8-Styryl-substituted coralyne derivatives as DNA binding fluorescent probes.RSC Adv. 2017 Feb 8;7(18):10660-10667.
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5008 mL | 12.5041 mL | 25.0081 mL |
| 5 mM | 0.5002 mL | 2.5008 mL | 5.0016 mL |
| 10 mM | 0.2501 mL | 1.2504 mL | 2.5008 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。